-- 泰克資源（TECK-B.TO）週四稍早公佈，受創紀錄的季度銅銷量提振，第一季調整後獲利大幅成長。截至發稿時，該公司美股盤前交易下跌1.2%。 歸屬於股東的調整後利潤為8.58億加元，合每股1.75美元，較上年同期的3.03億加元（合每股0.60美元）大幅成長。該業績超過了FactSet匯總的第一季非GAAP每股收益預期1.12美元。 營收為39.4億美元，高於去年同期的22.9億美元。該業績也超過了FactSet匯總的第一季銷售額預期32.3億美元。 調整後EBITDA為20.9億美元，高於去年同期的9.27億美元。成長主要得益於創紀錄的季度銅銷售、大宗商品價格上漲以及副產品收入增加。 克布拉達布蘭卡銅礦第一季銷售達70,300噸，創季新高。該季度產量為55,500噸。 泰克公司維持2026年銅產量預期，即455,000至530,000噸。
Related Articles
Asia
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
$ASX:ONE
Asia
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
$ASX:PAR
Asia
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.
$SHA:600703